Eli De Los Pinos

Eli de los Pinos is the founding CEO of Aura, which she created from the ground up: She developed the company concept collaborating with Lasker award winner Dr. John Schiller at the National Cancer Institute and spearheaded fundraising efforts, raising a total of $140M in multiple rounds of financing. Prior to founding Aura, she worked in Eli Lilly & Co.’s oncology business unit, where she was part of the leadership team responsible for the market launch in Europe of Alimta, a drug for the treatment of lung cancer. Earlier in her career, Eli worked as a post-doctoral fellow at the Institute of Cancer Research in London. She previously completed fellowships at the Mount Sinai School of Medicine Institute of Molecular Medicine and at the Georgetown School of Medicine. Eli holds a Ph.D., magna cum laude, in Molecular Biology from the University of Barcelona and an MBA from IE Business School.

She is a member of the board of overseers at the Museum of Science, Boston. Eli has also been named to Boston Business Journal's “Top 40 under 40” list; as a Mass High Tech “Woman to Watch”; as a “Technology Pioneer” by the World Economic Forum; and as one of Goldman Sachs’ “100 Most Intriguing Entrepreneurs”.

Eli first met Henri in 2010 right after moving to Boston from Spain to start Aura. As a first time female CEO, Eli was privileged to have Henri’s mentorship in those early and challenging years guiding her to define the company’s strategy and Board of Directors, actively participating in her seed round of angel investors and in every financing round thereafter, introducing her to his closest business network and later becoming a Board member and key strategic advisor.